-
公开(公告)号：US20230002726A1
公开(公告)日：2023-01-05
申请号：US17903271
申请日：2022-09-06
Applicant: ICHILOV TECH LTD.
Inventor： Nadir ARBER , Shiran SHAPIRA , Oren BOGIN
Abstract: Xenograft egg models comprising a fertilized non-mammalian egg comprising an ablated immune system, a first plurality of mammalian cells and a second plurality of mammalian cells, wherein the second plurality comprises immune cells are provided. Methods of producing the xenograft egg model as well as using the xenograft egg model for screening are also provided.
-
公开(公告)号：US20210324339A1
公开(公告)日：2021-10-21
申请号：US17327719
申请日：2021-05-23
Applicant: Ichilov Tech Ltd.
Inventor： Nadir ARBER , Shiran SHAPIRA
Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US20240043555A1
公开(公告)日：2024-02-08
申请号：US18229821
申请日：2023-08-03
Applicant: ICHILOV TECH LTD.
Inventor： Idit F. SCHWARTZ , Nadir ARBER , Doron SCHWARTZ , Lior YANKELSON
IPC: C07K16/28 , A61K31/7105 , A61P13/12
CPC classification number: C07K16/2896 , A61K31/7105 , A61P13/12 , C07K2317/76
Abstract: Provided herein is a method for treating or preventing a kidney disease or injury in a subject in need thereof, the method including administering to the subject a therapeutically effective amount of pharmaceutical composition including a CD24 inhibitor. Further provided is a method for inhibiting a damage associated molecular pattern (DAMP) in a subject, including administering to the subject a therapeutically effective amount of pharmaceutical composition including a CD24 inhibitor.
-
公开(公告)号：US20210322483A1
公开(公告)日：2021-10-21
申请号：US17186039
申请日：2021-02-26
Applicant: Ichilov Tech Ltd.
Inventor： Nadir ARBER , Shiran SHAPIRA
Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.
-
公开(公告)号：US20240002810A1
公开(公告)日：2024-01-04
申请号：US18224131
申请日：2023-07-20
Applicant: Ichilov Tech Ltd.
Inventor： Nadir ARBER , Shiran SHAPIRA
CPC classification number: C12N5/0686 , C12N5/0656 , C07K14/71 , C12N2501/998 , C12N2500/90 , C12N2501/33 , C12N2501/599
Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.
-
公开(公告)号：US20230233618A1
公开(公告)日：2023-07-27
申请号：US18114317
申请日：2023-02-27
Applicant: Ichilov Tech Ltd.
Inventor： Nadir ARBER , Shiran SHAPIRA
CPC classification number: A61K35/33 , A61P37/06 , A61P31/14 , A61P11/00 , A61K9/0043 , A61K9/007 , A61K9/1271 , A61K38/177 , C12N5/0656 , C12N2510/00
Abstract: A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed.
-
公开(公告)号：US20220112303A1
公开(公告)日：2022-04-14
申请号：US17560582
申请日：2021-12-23
Applicant: Ichilov Tech Ltd.
Inventor： Nadir ARBER , Shiran SHAPIRA , Diana KAZANOV
Abstract: An anti-CD24 antibody is provided. Accordingly, there is provided an antibody comprising an antigen recognition domain which specifically binds CD24 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 2, 3 and 4 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 6, 7 and 8 arranged in a sequential order from N to C on a heavy chain of said antibody. Also provided are polynucleotides encoding the antibody, host cells expressing the antibody the uses thereof.
-
-
-
-
-
-
Search Results
7
records
(took 0.016 seconds)
